-
Allergan, Inc. v. Sandoz Inc DC CAFC
- 2:09-cv-00097
- E.D. Tex.
- Judge: Rodney Gilstrap
- Filed: 04/07/2009
- Closed: 09/02/2016
- Latest Docket Entry: 10/31/2016
- PACER
1
Plaintiff
3
Defendants
0
Accused
Products
4
Patents-in-Suit
2,706
Days in
Litigation
-
Allergan, Inc. v. Sandoz Inc DC CAFC
- 2:09-cv-00097
- E.D. Tex.
- Judge: Rodney Gilstrap
- Filed: 04/07/2009
- Closed: 09/02/2016
- Latest Docket Entry: 10/31/2016
- PACER
Severance To
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A composition comprising 0.2% brimonidine (w/v) and 0.5% timolol (w/v), in a single composition.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 2 |
The composition of claim 1 further comprising from 0.001% to 0.01% benzalkonium chloride.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 3 |
The composition of claim 2 comprising about 0.005% benzalkonium chloride.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 4 |
The composition of claim 1 wherein brimonidine is brimonidine tartrate and timolol is timolol maleate.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 5 |
The composition of claim 1 which is useful for treating ocular hypertension.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 6 |
The composition of claim 1 which is useful for treating glaucoma.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 7 |
An article of manufacture comprising packaging material and a composition within said packaging material, wherein said composition comprises 0.2% brimonidine by weight and 0.5% timolol by weight, in a single composition, and wherein said packaging
view more
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 8 |
The article of manufacture of claim 7 wherein the composition further comprises from 0.001% to 0.01% benzalkonium chloride.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 9 |
The article of manufacture of claim 7 wherein the composition further comprises about 0.005% benzalkonium chloride.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A composition comprising about 0.2% timolol by weight and about 0.5% brimonidine by weight as the sole active agents, in a single composition.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 2 |
The composition of claim 1 further comprising from 0.001% to 0.01% benzalkonium chloride.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 3 |
The composition of claim 2 comprising about 0.005% benzalkonium chloride.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 4 |
An article of manufacture comprising packaging material and a composition within said packaging material, wherein said composition comprises about 0.2% timolol by weight and about 0.5% brimonidine by weight, in a single composition, and wherein said
view more
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 5 |
The article of manufacture of claim 4 wherein the composition further comprises from 0.001% to 0.01% benzalkonium chloride.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| 6 |
The article of manufacture of claim 5 wherein the composition further comprises about 0.005% benzalkonium chloride.
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A method of treating glaucoma or ocular hypertension which comprises topically administering a therapeutically effective amount of a single composition comprising brimonidine at a concentration of about 0.2% by weight and timolol at a concentration
view more
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 4 |
A method of reducing the number of daily topical ophthalmic doses of brimondine administered topically to an eye of a person in need thereof for the treatment of glaucoma or ocular hypertension from 3 to 2 times a day without loss of efficacy,
view more
|
Enforceable and Valid
Entry 262 Entry 260 Entry 259 |
-
Infringement
Alcon Laboratories Incorporated
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,030,149 B2 |
4
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,320,976 B2 |
1
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,323,463 B2 |
1, 2, 3, 4, 5, 6
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,642,258 B2 |
1, 2, 3, 4, 5, 6, 7, 8, 9
|
Infringement
Entry 259
|
Alcon Research Limited
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,030,149 B2 |
4
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,320,976 B2 |
1
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,323,463 B2 |
1, 2, 3, 4, 5, 6
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,642,258 B2 |
1, 2, 3, 4, 5, 6, 7, 8, 9
|
Infringement
Entry 259
|
Allergan, Inc. (Canada)
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,030,149 B2 |
4
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,320,976 B2 |
1
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,323,463 B2 |
1, 2, 3, 4, 5, 6
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,642,258 B2 |
1, 2, 3, 4, 5, 6, 7, 8, 9
|
Infringement
Entry 259
|
Apotex Corporation
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,030,149 B2 |
4
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,320,976 B2 |
1
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,323,463 B2 |
1, 2, 3, 4, 5, 6
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,642,258 B2 |
1, 2, 3, 4, 5, 6, 7, 8, 9
|
Infringement
Entry 259
|
Apotex Inc.
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,030,149 B2 |
4
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,320,976 B2 |
1
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,323,463 B2 |
1, 2, 3, 4, 5, 6
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,642,258 B2 |
1, 2, 3, 4, 5, 6, 7, 8, 9
|
Infringement
Entry 259
|
Falcon Pharmaceuticals Limited
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,030,149 B2 |
4
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,320,976 B2 |
1
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,323,463 B2 |
1, 2, 3, 4, 5, 6
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,642,258 B2 |
1, 2, 3, 4, 5, 6, 7, 8, 9
|
Infringement
Entry 259
|
Sandoz Inc.
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic SolutionGeneric Combigan | US 7,030,149 B2 |
1, 2, 3, 4
|
Infringement
Entry 262Entry 259 Entry 260 Entry 261 |
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic SolutionGeneric Combigan | US 7,320,976 B2 |
1
|
Infringement
Entry 262Entry 259 Entry 260 |
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic SolutionGeneric Combigan | US 7,323,463 B2 |
1, 2, 3, 4, 5, 6
|
Infringement
Entry 262Entry 259 Entry 260 |
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic SolutionGeneric Combigan | US 7,642,258 B2 |
1, 2, 3, 4, 5, 6, 7, 8, 9
|
Infringement
Entry 262Entry 259 Entry 260 |
Watson Laboratories, Inc. (Connecticut)
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,030,149 B2 |
4
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,320,976 B2 |
1
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,323,463 B2 |
1, 2, 3, 4, 5, 6
|
Infringement
Entry 259
|
| 0.2% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution0.5% Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution | US 7,642,258 B2 |
1, 2, 3, 4, 5, 6, 7, 8, 9
|
Infringement
Entry 259
|